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2ABSTRACT 
Background: VA-2914 is a selective progesterone receptor modulator with potential contraceptive 
activity which induces amenorrhea while progestins cause endometrial spotting and bleeding. This 
abnormal bleeding due to progestins is a consequence of focal stromal proteolysis by increase in naked 
vessel size and density.  
Our objective was to quantify the effects of VA-2914 on endometrial vascularisation, fibrillar matrix 
and VEGF-A expression in endometrial biopsies from 41 women before and after 12 weeks daily 
treatment with a placebo or 2.5 mg, 5 mg or 10 mg VA-2914.  
Methods: Collagen fibrillar network was stained by silver impregnation. Vessel area, density and 
structure were quantified with a computer-assisted image analysis system after double immunostaining 
using an anti-von Willebrand Factor (endothelial cells) and an anti-alpha Smooth Muscle Actin 
(vascular smooth muscle cells) marker antibody. VEGF-A mRNA were quantified by RT-PCR and 
localized by immunohistochemistry. 
Results:  The endometrial vessels, collagen network and mRNA levels of VEGF-A were identical 
during the luteal phase at baseline and in VA-2914 treated women. VEGF-A distribution was 
unchanged. 
Conclusions: VA-2914 doesn’t alter the endometrial matrix and cells and does not modify the 
endometrial vessel morphology as compared to baseline biopsies.  
3Introduction 
Ovarian estrogens induce endometrial proliferation during the proliferative phase of the 
menstrual cycle. After ovulation, progesterone induces glandular secretion and stromal (pre)-
decidualization. In the absence of embryo implantation, the fall of both ovarian steroids in the late 
secretory phase triggers a cascade of events leading to vascular damage, proteolytic breakdown, 
shedding of the functional layer and menstrual bleeding. Irregular extracellular matrix breakdown and 
bleeding between menstruations are common disorders that occur in diverse endometrial pathologies 
or upon progestin treatment (1).  
Progestin administration causes endometrial vessel remodelling characterized by an increased 
number of dilated and “naked” vessels devoid of pericytes that are associated with endometrial 
bleeding (2). 
Progesterone receptor ligands include not only pure agonists or antagonists (PA) but also 
compounds with mixed activity. They are all belonging to the class of selective progesterone receptor 
modulators (PRMs). Many PRMs display direct antiproliferative effects in the endometrium justifying 
their possible use in the treatment of endometriosis and myoma associated bleeding. They also 
suppress late follicular development, block the LH surge and retard endometrial maturation, which 
renders them potential estrogen-free contraceptive drugs (3). 
VA-2914 is a steroid derived from 19-norprogesterone with potent in vitro and in vivo
progesterone antagonist activity (4,5). Acute and chronic toxicology studies in animals indicate a 
satisfactory safety profile, with considerably less antiglucocorticoid activity in cell culture (4) and in 
the rat (6) than that of mifepristone. It inhibits ovulation in rats in a dose-dependent manner upon 
single-dose oral administration and exhibits, by a decrease in implantation sites, an antifertility activity 
during continuous low-dose administration (7). VA-2914 is also effective as postcoital contraception 
in animal models (6,7) and in women (8). 
A series of Phase I clinical studies has been performed to determine the effects of VA-2914 on 
ovulation and endometrial maturation in women (9). We recently evaluated the effects of VA-2914, 
administrated continuously for 3 months, on ovulation and endometrial maturation in 46 normal 
women. Anovulation was observed in 80% of women in the 5 and 10 mg groups. Plasma estradiol 
levels remained in the physiological follicular phase range throughout treatment. No endometrial 
hyperplasia was noted. Amenorrhea occurred in 82 and 90% of women in the 5 and 10 mg groups 
(10).  
In this study, we evaluate the effects of low dose VA-2914 on the degradation of the 
endometrial matrix as well as  on endometrial vessel characteristics and on the expression of VEGF-A, 
an angiogenic cytokine known to play a key role on blood vessel growth and maturation (11). 
4Materials and Methods 
Patients 
The study was approved by the Ethics Committees at the University of Liege and Saint-
Antoine Hospital of Paris. Written informed consent was obtained from each subject. 46 women, aged 
18-35 years, with documented regular ovulatory menstrual cycles (25-32 days), within 20% of ideal 
body weight, not currently using an intrauterine device, and not having used reproductive hormonal 
medications or glucocorticoids for at least 12 weeks before the study, were randomly assigned to 
either a placebo or one of the three treatment groups (2.5 mg, 5 mg, or 10 mg/d VA-2914 - HRA 
Pharma, Paris, France). The therapy was started on the first or second day of menstrual bleeding 
following a baseline observational cycle and taken daily for 12 weeks. Women agreed to prevent 
pregnancy by abstinence or use of barrier contraception, or they were protected by tubal ligation or 
partner vasectomy. An endometrial biopsy was performed on day 6 to 8 after the LH surge determined 
by an urinary test during baseline cycle and treatment month 3. Endometrial biopsy was performed on 
treatment day 77 in the absence of detectable urinary LH surge during treatment month 3. 
Hormonal analysis 
E2 was measured by a direct RIA using Diasorin reagents (Anthony, France). The cross 
reactivity of estrone and estriol was only 0.6%. CVs at the level of 50 pmol/l were 3.6 and 10.4 
respectively, and at the level of 260 pmol/l, 2.9 and 6.8%, respectively. 
Progesterone was measured by RIA using CIS biointernational reagents (Gif sur Yvette, 
France). The only significant cross reacting steroids were: deoxycorticosterone 6.2%, 20alpha-
dihydroprogesterone 2.2% and 6beta-dihydroprogesterone 2.1%. CVs at the level of 10 ng/ml were 3.5 
and 4.5, respectively, and at the level of 18.8 ng/ml, 4.4 and 4%, respectively (10). 
Endometrial tissues 
Human endometrial biopsies were obtained from 41 women who completed the study with a 
Cornier Pipelle suction curette (C.C.D. International, Paris, France). A fragment was immediately snap 
frozen and stored in liquid nitrogen until analysis. The other part of the biopsy was fixed in 4% 
formaldehyde solution in phosphate buffer saline (PBS) and embedded in paraffin. Histological 
sections were stained with hematoxylin and eosin. Specimens were evaluated in a blinded fashion by 
two independent pathologists who classified them as proliferative or early (days 17-19), mid (days 20-
22) or late (days 24-26) secretory according to classical criteria (12). The immunohistology and 
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and with a mean number of gland sections of 100. 
Von Willebrand Factor/alpha-Smooth Muscle Actin double immunostaining 
Serial sections were mounted on silanized slides and used for immunohistochemistry. 
Endometrial vessels were identified by double immunostaining of endothelial cells and smooth muscle 
cells. The primary antibodies (Abs) used were a rabbit polyclonal anti-human von Willebrand Factor 
(vWF, A082, Dako, Denmark) and a mouse monoclonal anti-alpha Smooth Muscle Actin (αSMA, 
clone 1A4, A2547, Sigma-Aldrich, USA). Slides were washed in Tris-HCl, pH 7.6 between all steps 
unless otherwise stated. Endogenous peroxidase was blocked with 3% H2O2 for 20 min at room 
temperature (RT). Slides were incubated with normal sheep serum (NSS) (Hormonology laboratory, 
Marloie, Belgium) for 30 min at RT, directly followed by vWF antibody (1/500 in NSS/Tris 10%) 
overnight at 4°C. A swine anti-rabbit immunoglobulin conjugated to peroxidase (P0217, Dako, 
Denmark) was used as a secondary antibody. DAB+ (Liquid DAB+ substrate chromogen system, 
K3468, Dako, Denmark) was applied for 15 min at RT in the dark as a chromogen and sections were 
rinsed in H2O. Slides were incubated with normal goat serum (NGS) (Hormonology laboratory, 
Marloie, Belgium) before incubation with the second primary antibody, αSMA (1/400 in NGS/Tris 
10%) for 90 min at 37°C. A goat anti-mouse Ab conjugated to biotin (E 0433, Dako, Denmark) diluted 
1/400 in Tris buffer for 30 min at RT was used as a secondary Ab, followed by an incubation for 30 
min at RT with streptavidin-alkaline phosphatase (D 0396, Dako, Denmark) diluted 1/500. Finally, 
Fast Red chromogen system (K4016, Dako, Denmark) was applied for 10 min at RT in the dark. 
Sections were rinsed in H2O and mounted in Aqua Polymount (Polysciences, Inc., Warrington, PA). 
Negative control was performed by replacing each primary antibody with normal serum. 
VEGF-A  immunohistochemistry 
VEGF-A protein was localized in sections of paraffin-embedded endometrial biopsies. 
Sections were stained with VEGF-A antibody by the following steps. After dewaxing and rehydrating, 
tissue sections were subjected to antigen retrieval in pressure cook at 1.4 bar and 126°C for 11 min 
using citrate buffer and were then allowed to cool for 20 min. Endogenous peroxidase were blocked in 
3% H2O2 for 20 min at RT and non-specific binding of the primary antibody was blocked with 10% 
BSA. Incubation with rabbit polyclonal anti-human VEGF-A Ab (A-20, Santa Cruz Biotechnology, 
CA, USA) diluted 1/50 was conducted 60 min at RT. Sections were washed in PBS (5x 5 min) before 
incubation with the secondary Ab (goat anti-rabbit ENVISION/HRP, K4003, DAKO, Denmark) for 
30 min at RT. Finally, staining was revealed with DAB system and sections were counterstained with 
haematoxylin.    
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system. This scoring system is a standard method used in previous studies (13-16), and a high 
correlation has been demonstrated between objectively measured immunoreactivity (image analysis) 
and semi-quantitative scoring of immunostaining patterns (16). Immunostaining intensity and 
distribution of epitopes in all tissue sections were assessed on a four-point scale: 0 = no staining, 1 = 
mild staining, 2 = moderate staining and 3 = intense staining and expressed as a mean score and range. 
VEGF-A mRNA expression 
Frozen tissue was pulverized using a Dismembrator (B. Braun Biotech International, GmBH, 
Melsungen, Germany) and suspended in lysis buffer (5 M guanidine thiocyanate, 25 mM sodium 
citrate, 17 mM N-lauroylsarcosine and 0.1 M 2-mercaptoethanol [pH 7]). Total RNA was purified by 
‘Qiagen’ method (Qiagen Benelux). The concentration and purity of RNA was determined by 
spectrophotometry. RT-PCR amplification was performed using GeneAmp Thermostable rTth reverse 
transcriptase RNA PCR kit (Perkin-Elmer, Branchburg, NJ) and the following specific pair of primers: 
VEGF-A: 5’-TCTACCTCCACCATGCCAAGT-3’ and 5’-GCTGCGCTGATAGACATCCA-3’ (104 
base pair product) and 28S: 5’-GTTCACCCACTAATAGGGAACGTGA-3’ and 5’-
GATTCTGACTTAGAGGCGTTCAGT-3’ (212 base pair product). Reverse transcription was 
performed from 10ng RNA total at 70°C for 15 minutes, followed by 2 min at 95°C to denature DNA. 
PCR amplification was run as follows: 15 sec at 94°C, 30 sec at 60°C and 15 sec at 72°C during 31 
cycles for VEGF-A and 15 sec at 94°C, 20 sec at 68°C, and 10 sec at 72°C during 15 cycles for 28S, 
and followed by a final 2 min extension step at 72°C. RT-PCR products were resolved on 10% 
polyacrylamide gels and analysed using a Fluor-S Multimager (BioRad, Hercules, CA) after staining 
with Gelstar dye (FMC BioProducts, Rockland, ME). Products were quantified by normalization with 
respect to 28S ribosomal RNA. The levels of expression were compared at baseline and in a combined 
group of women exposed to various doses of VA-2914.  
Staining of the argyrophilic fibrillar network 
Silver impregnation of histological sections was performed as previously described (17). 
Image analysis and measurement 
Slides were observed with an Olympus microscope (Omnilabo, Aartselaar, Belgium) and the 
entire section (Mean area 25 mm2) was analysed at magnification of 400X. Vessels were identified by 
positive von Willebrand factor staining and the presence of pericytes was documented according to the 
αSMA staining as previously described in details (2). Briefly, a coating of the endothelial cells with 
7αSMA positive cells (pericytes) was considered as terminal venules or arterioles, while ‘naked’ 
vessels were considered to be capillaries. A score (0 or 1) was attributed to blood vessels according to 
absence or presence of αSMA staining. Vessels were counted in the entire biopsy.  
The contour of each vessel type was drawn manually at 400X magnification using Photoshop 
software by two different colours: blue for αSMA negative vessels (score 0), red for αSMA stained 
vessels (score 1) and green for tissue boundaries (figure 1A). Then, the colour image was decomposed 
into its three components: red (R), green (G) and blue (B) (18). Figures 1 B and C show binary images 
of vessels scored 0 and 1, respectively. 
The area of each vessel section and the relative vascular area, defined as the ratio of vessel 
section surface to total tissue area, were measured in each binary image. Image processing and 
measurements were performed with the software Aphelion 3.2 from Adsis (France) on a PC. 
Statistical analysis 
The parameters were expressed in terms of the mean ± standard error.  Analyses for statistical 
significance were evaluated by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. 
Then, for comparison between two groups, Mann-Whitney U test and paired Wilcoxon were used. 
Statistical significance was set at p < 0.05. 
Results  
Patients and endometrial histology 
Patient’s characteristics and endometrial histology are described in Table I and have been 
reported in details elsewhere (10). Briefly, all women in the placebo group and most patients (9/11) 
exposed to VA-2914 2.5 mg/d experienced normal menstrual cycles, while amenorrhea was observed 
in majority of women receiving 5 or 10 mg/d (Table I). During the baseline cycle, thirty-two biopsies 
showed typical features of the mid-secretory phase and one showed a polyp. No tissue could be 
obtained from 8 women. After 12 weeks of treatment with VA-2914, 17 biopsies were classified as a 
secretory pattern and 1 as proliferative. No tissue was obtained from 11 patients. Patients with polyps 
were excluded for further analysis. 
The histological features of endometria in women at baseline during the mid secretory phase 
(figure 2A) and after 12 weeks of continuous treatment with VA-2914 (2.5-10 mg/d) (figures 2B-D) 
were similar. 
Estradiol and progesterone plasma levels during the third treatment month are described in 
Table II. All women in the placebo treated group exhibited an endometrial secretory pattern with E2 
and progesterone plasma levels typical of a mid luteal phase. Among the 6 women exposed to VA-
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endometrium also showed the expected secretory pattern. Three other women in that group had 
progesterone plasma levels below the range of an ovulatory cycle (respectively 0, 0 and 2 ng/ml). In 2 
of them an endometrial pattern of a secretory phase was documented. Among the 13 women exposed 
to VA-2914 5 or 10 mg/d, only 3 had progesterone plasma levels above 6 ng/ml (respectively 24, 16 
and 13 ng/ml). In the 10 other women, progesterone plasma levels was below the detection limit. The 
histological demonstration of a secretory pattern in these women should therefore be ascribed to a VA-
2914 injury. In all women, the estradiol plasma levels were in the range of a spontaneous mid 
follicular phase. Altogether these data suggest that exposure to 5-10 mg/d VA-2914 blocks ovulation 
but does not induce the histological changes classically elicited by anti-gonadotropic progestins. 
Stromal breakdown and fibre lysis 
Staining of argyrophilic fibrillar network documented the integrity of the collagen-rich fibrillar 
network in all biopsies at baseline and after treatment with placebo or all doses of VA-2914 (figures 
2E-F). This is in sharp contrast with the stromal breakdown and extensive endometrial matrix 
proteolysis in women with progestin-only contraceptives (1,19). This indicates that VA-2914 does not 
elicit the extensive endometrial stromal breakdown observed after progestin exposure.  
Microvessel density and area 
Altogether more than 12,000 vessel sections were counted and characterized. Capillaries were 
identified by the isolated presence of vWF positive endothelial cells (figure 2G) while a continuous 
layer of αSMA positive cells coating the endothelial cells characterized small arterioles and venules 
(figure 2H).  
The relative vascular area (ratio of vessel section surface to total tissue area) was determined 
in endometrial biopsies of 32 women at baseline during the mid-secretory phase and after treatment 
with VA2914 (figures 3A-B). At baseline, about 80% of the vascular areas were occupied by vessels 
coated with αSMA positive cells. After 12 weeks treatment with various doses of VA-2914, this 
proportion remained unchanged (figure 3B).  
The mean vessel section areas were determined by computer assisted method (figure 3C). 
Vessels coated with smooth muscle cells were larger than “naked” capillaries in all groups. Their 
respective sizes were identical at baseline and during treatment with VA-2914. No difference in 
vessels counts, density and size was observed with a Mann-Whitney test. The comparison of values 
from each individual woman at baseline and after treatment by a paired Wilcoxon test failed also to 
show a significant difference. 
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During the baseline cycle, VEGF-A was strongly localized in the apical part of the cytoplasm 
of the surface epithelium [score 2.5, (1-3)] and of glandular epithelial cells [score 2.9, (2-3)]. Mild 
expression was also found in the stroma [score 0.8, (0-1)] and endothelial cells [score 0.8, (0-1)] 
(Table III, figure 2I). VEGF-A localization remained unchanged in all cellular compartments 
following 12 weeks of treatment with placebo or VA-2914 (Table III, figure 2J).
VEGF-A expression 
The mRNA expression of VEGF-A was analysed by RT-PCR in endometrial tissue from 11 
women at baseline and from 8 women treated with various doses of VA-2914. The VEGF-A mRNA 
levels remained unchanged (data not shown).  
Discussion 
VA-2914 is a new PRM that is undergoing clinical testing. Endometrial changes associated 
with a minimum of three months of chronic treatment with PRMs including VA-2914 were recently 
evaluated by a panel of pathologists. Biopsies exhibited an unusual architecture characterized as 
glandular dilatation and little evidence of mitosis, consistent with the proposed antiproliferative effect 
of PRMs (20). The specific aspect observed in endometrial biopsies during PRM treatment are now 
described as PRMs Associated Endometrial Changes (PAEC) (21). In our study, the endometria were 
mostly secretory at doses of 2.5 and 5 mg VA-2914 independently of E2 and progesterone levels 
(Table II). Atrophy has been described at 10 mg dosage (Table I). In this study, respectively 82 and 
90% of women became amenorrheic during the 12 weeks daily treatment with 5 or 10 mg (see also 
(10)). Athough a comparison between endometria after treatment with oral VA-2914 and after 
treatment with an oral progestin such as oral levonorgestrel is an appropriate design for a subsequent 
clinical study, this phase IIA protocol aimed at evaluating in a limited set of women the impact of VA-
2914 upon the endometrial histology, ovulation and endocrine ovarian activity in women with 
documented spontaneous ovulatory cycle. This first clinical study indicates that a 12 weeks exposure 
to VA-2914 5 or 10 mg/d causes anovulation, amenorrhea and a persistent estradiol secretion with an 
endometrial pattern that closely resembles that of a spontaneous ovulatory cycle during the mid luteal 
phase. This pattern is strikingly distinct from that observed with other PRMs that cause endometrial 
hyperplastic changes which are worrisome for chronic administration (22).
Argyrophilic staining of the collagen fibrillar network showed no evidence of endometrial 
matrix degradation during the mid-secretory phase of spontaneous ovulatory cycle (control) or in 
women exposed to VA-2914. Focal stromal breakdown, i.e. menstrual-like tissue collapse and 
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fragmentation, and lysis of the collagen-rich argyrophilic fibrillar network are classically observed in 
endometrial biopsies performed at menstruation or at the start of a bleeding episode in women 
receiving subcutaneous or intrauterine levonorgestrel as progestin (1). Such focal and stromal 
breakdown and collagen fiber lysis are evidenced in bleeding endometria and associated with higher 
activities of collagenase-1 and gelatinases A and B together with lower tissue inhibitor of 
metalloproteinase-1 than in non-bleeding endometria (1,19). The absence of matrix remodelling and 
collagen lysis in normal secretory endometria and in women receiving VA-2914 suggests that the 
endometrial changes elicited by menstruation and/or prolonged progestin exposure are absent in our 
patients. 
We have shown previously that extensive endometrial remodelling was induced by exogenous 
LNG administration in the form of an intrauterine system (2). Endometrial samples obtained in 8 
women exposed for 1 month to LNG-IUS displayed an 11.5-fold increase in small naked vessel 
number and a 6-fold increase in pericytes coated vessels. In women using long-term LNG-IUS, a 4-
fold increase in the number and size of fragile capillaries (2). We hypothesized that such increased 
number of fragile “naked” capillaries could easily be injured and responsible for bleeding. We 
therefore compared in this study the impact of VA-2914 or of endogenous progesterone during the 
mid-secretory phase of spontaneous ovulatory cycle (baseline cycle) on the pattern of endometrial 
vessels. Endometrial VA-2914 exposed women exhibited identical blood vessel number, area, density 
and maturation in comparison to the pattern of normal spontaneous secretory endometrium under the 
influence of endogenous estradiol + progesterone. This pattern of endometrial vessels was observed 
independently of the endogenous levels of E2 and progesterone (Table II). In the same patients, we 
documented previously the persistence of physiological estradiol levels (10). The similarity of pattern 
in the presence of endogenous progesterone or of VA-2914 is somewhat surprising since VA-2914 is 
not a progestin but a selective modulator of the progesterone receptor. This pattern may contribute to 
explain the high level of amenorrhea observed in our patients. Additional clinical study comparing the 
impact of orally given synthetic progestin in the presence or absence of VA-2914 will be necessary to 
more precisely delimit the impact of this new drug on the endometrial physiology.  
The presence of VEGF-A mRNA and protein have been demonstrated in the human 
endometrium throughout the menstrual cycle (23). Most studies including ours, have shown 
predominant localization of VEGF-A in the apical part of surface and glandular epithelial cells 
compared to the stroma (figure 1E and (24)). In this study, VA-2914 did not modify the VEGF-A 
distribution nor its relative staining intensity. This PRM thus acts in a way distinct from that of 
mifespristone which  increases  microvessel density and  decreases stromal VEGF in endometria of 
women exposed for 120 days to mifepristone (13).  
Altogether, this preliminary phase II study performed on a limited number (46) of women 
confirms that the PRM VA-2914 maintains matrix and vessel stability, does not impair the expression 
of the angiogenic cytokine, VEGF-A, and allows the maintenance of a stable vascular network that 
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closely resembles that observed during the secretory phase of spontaneous ovulatory cycle despite 
anovulation and amenorrhea. This drug could, in this way, be associated with an improved clinical 
tolerance profile since it is devoid of the endometrial matrix and vascular remodelling associated with 
menstruation or with the bleeding conveyed by withdrawal of progesterone. 
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Figure legends
Figure 1: Image analysis and vessel quantification. (A) The contour of each type of vessel 
was drawn manually in the original image by the following different colors: blue for vessels 
scored 0 and red for vessels scored 1. Green delineates the area of tissue in which 
measurements are performed. (B) Binary images of score 0 vessels and (C) binary image of 
score 1 vessels contained in the original image.   
Figure 2: (A-D) Representative fields of hematoxylin-eosin-stained histological sections of 
secretory endometrium during baseline cycle (A) and after 12 weeks with 2.5 mg/d (B), 5 
mg/d (C) and 10 mg/d VA-2914. Original magnification 200X. (E-F) Stromal collagen-rich 
argyrophilic fibrillar network using silver impregnation. Endometrium after 12 weeks 
treatment with placebo (E) and 10 mg/d VA-2914 (F). Original magnification, 200X. (G-H) 
Immunolocalization of alpha-Smooth Muscle Actin (αSMA), von Willebrand Factor (vWF) 
and VEGF in endometrium. In the double immunostaining, αSMA positive cells (pericytes) 
were labelled in red and vWF positive cells (endothelial cells) were stained in brown. αSMA 
negative vessels (G), vessels with continuous layer of αSMA positive perivascular cells (H). 
Original magnification 400X. (I-J) Immunolocalization of VEGF-A in endometrial glands 
(Gl.), stroma (Str.), surface epithelium (Surf.) and vascular endothelium (VE) during the 
baseline cycle (I) and after treatment with 10 mg/d VA-2914 (J). The VEGF-A distribution 
was identical in endometrium of women treated with 2.5 or 5 mg/d VA-2914 (data not 
shown). Original magnification, 200X. 
Figure 3: Quantification of vessel types in endometrium at baseline or after 12 weeks 
treatment with VA-2914. (A) The relative vascular area represents the percentage of total 
tissue area occupied by vessels. It is calculated as the ratio between the vessel section surfaces 
15
x 100 to total tissue area. (B) The relative proportion of vessel types refers to the percentage 
of naked and pericytes coated vessels. (C) The mean vessel section area (μm2) represents the 
mean absolute area occupied by both types of vessels. These parameters were determined by 
computer assisted method for ‘naked’ capillaries (vWF+ only) and smooth muscle cells 
coated vessels (vWF+ and αSMA+) in endometrium collected during baseline cycle (n=32) 
and after 12 weeks treatment with VA-2914 at doses of 2.5 mg (n=6), 5mg (n=10) and 10 mg 
(n=3) (p>0.05). The vessel parameters of endometrium from women exposed to placebo (n=5) 
were identical to those of the baseline group (n=32) (data not shown). 
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Table I: Patient’s characteristics and endometrial histology at baseline cycle and during the third 










PATIENTS, n 41 9 11 12 9 
Age, Mean ± SD 26.0 ± 5.2 26.1 ± 3.9 23.8 ± 5.4 27.6 ± 5.2 26.4 ± 6.0 
Amenorrhea, n 0 0 2 9 9 
































Table II: Estradiol and progesterone plasma levels during the third treatment month with placebo or 
2.5 mg/d, 5 mg/d and 10 mg/d VA-2914. 





1 late secretory (day 24) 80 20 
2 early secretory (day 18) 180 18 
3 mid secretory (day 20) 70 14 
4 mid secretory (day 20) 60 21 
Placebo 
5 early secretory (day 18) 120 10 
1 mid secretory (day 20) 160 18 
2 early secretory (day 18) 100 9 
3 proliferative 200 0 
4 early secretory (day 18) 120 10 
5 mid secretory (day 20) 40 0 
2.5 mg/d  
VA-2914 
6 mid secretory (day 20) 100 2 
1 early secretory (day 18) 280 24 
2 mid secretory (day 20) 150 1 
3 mid secretory (day 20) 90 0 
4 mid secretory (day 20) 30 0 
5 late secretory (day 25) 50 0 
6 late secretory (day 25) 40 0 
7 late secretory (day 28) 30 16 
8 late secretory (day 23) 110 0 
9 late secretory (day 25) 260 0 
5 mg/d  
VA-2914
10 mid secretory (day 20) 40 0 
1 mid secretory (day 20) 200 0 
2 mid secretory (day 20) 160 13 
10 mg/d  
VA-2914
3 mid secretory (day 20) 40 0 
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Table III: Semiquantitative evaluation of VEGF-A immunolocalisation in endometrium during 
baseline and treatment cycles. Mean score (median) (p>0.05).
(0: absence of staining, 1: staining of <25% of the surface epithelium, or glands, or stroma, or 
endothelium, 2: staining between 25% and 50% of the specific structures and 3: strong >50% 
of the structures studied.)































































































































































2.5 mg/d 5 mg/d 10 mg/d
VA-2914 treatment(n=32)
(n=6) (n=10) (n=3)
B
